CRVS
Price
$8.00
Change
-$0.18 (-2.20%)
Updated
Nov 13 closing price
Capitalization
597.45M
111 days until earnings call
Intraday BUY SELL Signals
HIND
Price
$4.93
Change
-$0.39 (-7.33%)
Updated
Nov 13 closing price
Capitalization
27.48M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRVS vs HIND

Header iconCRVS vs HIND Comparison
Open Charts CRVS vs HINDBanner chart's image
Corvus Pharmaceuticals
Price$8.00
Change-$0.18 (-2.20%)
Volume$1.11M
Capitalization597.45M
Vyome Holdings
Price$4.93
Change-$0.39 (-7.33%)
Volume$32.02K
Capitalization27.48M
CRVS vs HIND Comparison Chart in %
CRVS
Daily Signal:
Gain/Loss:
HIND
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRVS vs. HIND commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a StrongBuy and HIND is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (CRVS: $8.00 vs. HIND: $4.93)
Brand notoriety: CRVS and HIND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 118% vs. HIND: 8%
Market capitalization -- CRVS: $597.45M vs. HIND: $27.48M
CRVS [@Biotechnology] is valued at $597.45M. HIND’s [@Biotechnology] market capitalization is $27.48M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileHIND’s FA Score has 1 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • HIND’s FA Score: 1 green, 4 red.
According to our system of comparison, HIND is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 4 TA indicator(s) are bullish while HIND’s TA Score has 3 bullish TA indicator(s).

  • CRVS’s TA Score: 4 bullish, 4 bearish.
  • HIND’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, CRVS is a better buy in the short-term than HIND.

Price Growth

CRVS (@Biotechnology) experienced а +2.30% price change this week, while HIND (@Biotechnology) price change was -12.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.47%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +62.00%.

Reported Earning Dates

CRVS is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+1.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRVS($597M) has a higher market cap than HIND($27.5M). CRVS YTD gains are higher at: 52.897 vs. HIND (19.283).
CRVSHINDCRVS / HIND
Capitalization597M27.5M2,171%
EBITDA-35.45MN/A-
Gain YTD52.89719.283274%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash74.4MN/A-
Total Debt1.08MN/A-
FUNDAMENTALS RATINGS
CRVS vs HIND: Fundamental Ratings
CRVS
HIND
OUTLOOK RATING
1..100
1686
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
65100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3743
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HIND's Valuation (27) in the null industry is somewhat better than the same rating for CRVS (69) in the Pharmaceuticals Major industry. This means that HIND’s stock grew somewhat faster than CRVS’s over the last 12 months.

CRVS's Profit vs Risk Rating (65) in the Pharmaceuticals Major industry is somewhat better than the same rating for HIND (100) in the null industry. This means that CRVS’s stock grew somewhat faster than HIND’s over the last 12 months.

CRVS's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as HIND (100) in the null industry. This means that CRVS’s stock grew similarly to HIND’s over the last 12 months.

CRVS's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as HIND (43) in the null industry. This means that CRVS’s stock grew similarly to HIND’s over the last 12 months.

CRVS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as HIND (100) in the null industry. This means that CRVS’s stock grew similarly to HIND’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSHIND
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 18 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signal:
Gain/Loss:
HIND
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GMWEX13.530.12
+0.86%
GuideMark® World ex-US Service
SMIPX15.140.04
+0.26%
Saratoga Mid Capitalization I
OISVX14.330.03
+0.21%
Optimum Small-Mid Cap Value Instl
JBAFX32.730.05
+0.15%
JHancock Balanced R4
FVCSX35.30N/A
N/A
Fidelity Advisor Value Strategies C

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
+0.12%
SYRE - CRVS
44%
Loosely correlated
+0.34%
IPSC - CRVS
44%
Loosely correlated
N/A
KRRO - CRVS
40%
Loosely correlated
-4.21%
RZLT - CRVS
40%
Loosely correlated
-0.40%
UPB - CRVS
40%
Loosely correlated
-0.25%
More

HIND and

Correlation & Price change

A.I.dvisor tells us that HIND and CRVS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIND and CRVS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIND
1D Price
Change %
HIND100%
+0.19%
CRVS - HIND
30%
Poorly correlated
+0.12%
ACET - HIND
20%
Poorly correlated
+6.24%
RNTX - HIND
4%
Poorly correlated
-2.68%
YDES - HIND
3%
Poorly correlated
N/A
LIMN - HIND
2%
Poorly correlated
+0.43%
More